Nikhil T. Pradhan

Senior Counsel

Nikhil T. Pradhan

Senior Counsel

Nikhil T. Pradhan is a senior counsel and intellectual property lawyer with Foley & Lardner LLP. He is a member of the Mechanical & Electromechanical Technologies Practice and Innovative Technology Sector. Nikhil leads teams for building patent portfolios across a broad range of technologies, including energy, automotive, aerospace, computer vision, machine learning, artificial intelligence, medical device and surgical methods, and control system technologies. Nikhil provides high-level intellectual property counseling, including competitive strategy, clearance, and invalidity/noninfringement opinions. He also provides counsel for litigation, post-grant proceedings, and transactional matters, including performing due diligence and preparing licensing and development agreements.

Nikhil provides expert counsel to clients across all sectors seeking to develop and deploy AI technologies. He helps clients create and execute on comprehensive risk management frameworks to address issues from data privacy and confidentiality obligations to negotiating licenses for external AI technologies to IP protection for AI innovations.

Nikhil was a summer associate with Foley in 2013. He also served as a summer associate with Ford Motor Company in 2012.

Prior to joining Foley, Nikhil served as an intellectual property intern with the U.S. Forest Service Patent Program. He completed a judicial externship with the Wisconsin State Court of Appeals. During law school, Nikhil worked as a graduate teaching assistant for the University of Wisconsin, Madison’s Chemical Engineering Department. He holds experience as a research intern for the MIT Center for Collective Intelligence (CCI).

28 February 2025 In the News

Nikhil Pradhan Assesses FDA AI Draft Drug Guidance's IP Impact

Foley & Lardner LLP senior counsel Nikhil Pradhan shared important context on the U.S. Food and Drug Administration’s draft guidelines for AI use in decision making within the pharmaceutical industry in the pharmaphorum article, “Regulating the invisible hand: Inside the FDA’s AI playbook.”
20 February 2025

Clarifying the Copyrightability of AI-Assisted Works

The U.S. Copyright Office has concluded that existing copyright legislation and principles are well-suited for the issue of AI outputs’ copyrightability.
13 February 2025 In the News

Nikhil Pradhan on FDA Draft AI Drug Guidance - 'The industry is very much evolving'

Foley & Lardner LLP senior counsel Nikhil Pradhan shared insight on recent draft guidance from the U.S. Food and Drug Administration's in the MedCentral article, "FDA Draft Guidance Addresses Drug Submissions that Use AI Data."
15 January 2025 Health Care Law Today

AI Drug Development: FDA Releases Draft Guidance

On January 6, 2025, the U.S. Food and Drug Administration released draft guidance titled Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products explaining the types of information that the agency may seek during drug evaluation.
18 December 2024 Innovative Technology Insights

AI in Drug Discovery: 2025 Outlook

Our team analyzes the trends impacting companies utilizing artificial intelligence for drug discovery.
03 October 2024 Innovative Technology Insights

I Build Generative AI Technology: Does California’s New Transparency Requirement Apply to Me?

FAQs for developers of generative AI models and applications.